Uganda

Health indicators are improving in certain regions of Uganda, yet many deaths are caused by preventable diseases such as malaria and HIV/AIDS. According to WHO, HIV/AIDS has a national prevalance of 5.4% and is the leading cause of death among adults, followed by tuberculosis (TB) and malaria. In addition, UNAIDS reports that HIV/AIDS is responsible for nearly half of the Ugandan orphan population, which exceeds an estimated two million. Uganda is one of 15 US President's Emergency Plan for AIDS Relief (PEPFAR) focus countries currently receiving support for comprehensive HIV/AIDS prevention, treatment and care programs.

CCGHE RESPONDS

CCGHE has partnered with Medical Education Services to All Ugandans (MESAU), a consortium of five Ugandan medical schools, to provide support among five strategic areas: monitoring and evaluation, research capacity building, IRB strengthening, curriculum development and information technology (IT)/distance learning. Accordingly, CCGHE and colleagues in Uganda have engaged in a number of in-country education, distance learning and mobile technology initiatives, including development of mHealth tools to optimize HIV prevention efforts, continuing clinical education conferences and courses, building in-country capacity in curriculum development and distance learning, and interprofessional team-building among physicians, nurses, pharmacists, medical students and administrators.

CCGHE-UGANDA ACTIVITIES

P2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum

Post Date: 
2021-05-18
   |      |   
Clinical Sites: 
IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women, studied the PK of more than 25 HIV and TB drugs in these women and published 27 manuscripts presenting these data. P1026s data was cited in 32% of the 76 perinatal...

P1070: Dose-Finding and Pharmacogenetic Study of Efavirenz in HIV-Infected and HIV/TB Co-Infected Infants and Children ≥ 3 Months to < 36 Months of Age

Post Date: 
2008-12-05
   |      |   
Clinical Sites: 
This study ended March 10, 2015. This multi-country trial was conducted in India, South Africa, Tanzania, Uganda, Zambia, and Zimbabwe, under the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and funded by the U.S. National Institutes of...

A5207: Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine

Post Date: 
2004-12-20
   |   
This study was terminated January 16, 2014; it was conducted under the AIDS Clinical Trials Group (ACTG) and funded by the U.S. National Institutes of Health. A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to other...

Isoniazid preventive therapy in HIV-infected pregnant and postpartum women

Post Date: 
2019-10-03
   |      |   
Clinical Sites: 
Publication: 
New England Journal of Medicine
New England Journal of Medicine: Dr. Amita Gupta and colleagues found that the current standard of care given to HIV+ pregnant women to prevent TB should wait until 12 weeks after delivery. The study underscores the need to include pregnant women in clinical trials.

Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial

Post Date: 
2016-03-19
   |      |   
Clinical Sites: 
Publication: 
The Lancet
Background: Mortality within the first 6 months after initiating antiretroviral therapy is common in resource-limited settings and is often due to tuberculosis in patients with advanced HIV disease. Isoniazid preventive therapy is recommended in HIV-positive adults, but subclinical...

Pooled individual data analysis of five randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission

Post Date: 
2012-10-19
   |      |   
Clinical Sites: 
Publication: 
Clinical Infectious Diseases
Background: In resource-limited settings, mothers infected with human immunodeficiency virus type 1 (HIV-1) face a difficult choice: breastfeed their infants but risk transmitting HIV-1 or not breastfeed their infants and risk the infants dying of other infectious diseases or...

Global health education for medical students: New learning opportunities and strategies

Post Date: 
2012-01-17
   |   
Publication: 
Medical Teacher
Background: A new course was offered to introduce basic global health concepts to all first year Johns Hopkins medical students, that took advantage of new distance learning capacity to connect medical students in Baltimore with students and faculty in Uganda, Ethiopia, Pakistan and India...

Twelve month follow-up of the SWEN randomized controlled trials: Differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count

Post Date: 
2011-03-27
   |      |   
Clinical Sites: 
Publication: 
AIDS Care
Objectives: We previously reported combined analysis of 6-week and 6-month endpoints of three randomized controlled trials [Six Week Extended Dose Nevirapine (SWEN) trials] that compared extended-dose nevirapine through 6 weeks of age to single-dose nevirapine to prevent HIV transmission via...

Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomized controlled trials

Post Date: 
2009-07-26
   |      |   
Clinical Sites: 
Publication: 
The Lancet
Background: UNICEF/WHO recommends that infants born to HIV-infected mothers who do not have access to acceptable, feasible, affordable, sustainable, and safe replacement feeding should be exclusively breastfed for at least 6 months. The aim of three trials in Ethiopia, India, and Uganda was...
Subscribe to RSS - Uganda